{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:24:17Z","timestamp":1785788657187,"version":"3.56.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>The findings of this study offer insights into the utilisation of remimazolam for sedation in paediatric patients with left-to-right shunt congenital heart disease (CHD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>\n                      To study the median effective dose (ED\n                      <jats:sub>50<\/jats:sub>\n                      ) and 95 percentile of the effective dose (ED\n                      <jats:sub>95<\/jats:sub>\n                      ) of remimazolam for successful sedation in children with CHD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DESIGN<\/jats:title>\n                    <jats:p>A nonrandomised, nonblinded study based on the Dixon sequential method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SETTING<\/jats:title>\n                    <jats:p>Tertiary hospitals in Zhengzhou, Henan Province, study dates: 20 October 2023 to 18 May 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS<\/jats:title>\n                    <jats:p>A total of 78 patients, comprising 32 males and 45 females, successfully completed the study. They were selected based on the following criteria: children aged 1 to 6\u200ayears with left-to-right shunt CHD; ASA physical status II-III. The key exclusion criteria were: history of allergy to sedative drugs; administration of sedative medications other than the study drug before surgery; severe pre-operative liver or kidney dysfunction; pre-operative bradycardia; and severe pre-operative respiratory diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>INTERVENTION<\/jats:title>\n                    <jats:p>The sedation status of the patients was observed for 5\u200amin after intravenous administration of different doses of remimazolam.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MAIN OUTCOME MEASURES<\/jats:title>\n                    <jats:p>\n                      The ED\n                      <jats:sub>50<\/jats:sub>\n                      and ED\n                      <jats:sub>95<\/jats:sub>\n                      of remimazolam for successful sedation in children with CHD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      The ED\n                      <jats:sub>50<\/jats:sub>\n                      (95% CI) of remimazolam for successful sedation in infants, toddlers and preschool children with CHD were 0.209 (0.184 to 0.234) mg\u200akg\n                      <jats:sup>\u22121<\/jats:sup>\n                      , 0.259 (0.234 to 0.284) mg\u200akg\n                      <jats:sup>\u22121<\/jats:sup>\n                      and 0.266 (0.207 to 0.325) mg\u200akg\n                      <jats:sup>\u22121<\/jats:sup>\n                      , respectively. ED\n                      <jats:sub>95<\/jats:sub>\n                      (95% CI) were 0.356 (0.282 to 0.672) mg\u200akg\n                      <jats:sup>\u22121<\/jats:sup>\n                      , 0.404 (0.330 to 0.741) mg\u200akg\n                      <jats:sup>\u22121<\/jats:sup>\n                      and 0.408 (0.334 to 0.752) mg\u200akg\n                      <jats:sup>\u22121<\/jats:sup>\n                      , respectively. No serious adverse reactions were observed with intravenous remimazolam.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      This study explored the ED\n                      <jats:sub>50<\/jats:sub>\n                      and ED\n                      <jats:sub>95<\/jats:sub>\n                      of remimazolam for pre-operative sedation in children with left-to-right shunt CHD. It provides guidance for pre-operative sedation medication in children with left-to-right shunt CHD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION<\/jats:title>\n                    <jats:p>https:\/\/www.chictr.org.cn\/<\/jats:p>\n                    <jats:p>Identifier: ChiCTR2300076458.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/eja.0000000000002183","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T04:01:40Z","timestamp":1744603300000},"page":"697-703","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Remimazolam for successful sedation in children with left-to-right shunt congenital heart disease"],"prefix":"10.1097","volume":"42","author":[{"given":"Ming","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongdang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"R1-20250702","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12471-013-0432-9","article-title":"Association between pulmonary hypertension and an atrial septal defect","volume":"21","author":"Post","year":"2013","journal-title":"Neth Heart J"},{"key":"R2-20250702","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/bja\/aev226","article-title":"Dexmedetomidine: review, update, and future considerations of paediatric perioperative and periprocedural applications and limitations","volume":"115","author":"Mahmoud","year":"2015","journal-title":"Br J Anaesth"},{"key":"R3-20250702","doi-asserted-by":"crossref","first-page":"e00080","DOI":"10.1161\/HHF.0000000000000080","article-title":"Pulmonary hypertension in congenital heart disease: a scientific statement from the American Heart Association","volume":"16","author":"Jone","year":"2023","journal-title":"Circ Heart Fail"},{"key":"R4-20250702","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/ALN.0000000000003103","article-title":"Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part I. Pharmacokinetics and clinical pharmacodynamics","volume":"132","author":"Sch\u00fcttler","year":"2020","journal-title":"Anesthesiology"},{"key":"R5-20250702","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/01.anes.0000267514.42592.2a","article-title":"Advances in and limitations of up-and-down methodology: a pr\u00e9cis of clinical use, study design, and dose estimation in anesthesia research","volume":"107","author":"Pace","year":"2007","journal-title":"Anesthesiology"},{"key":"R6-20250702","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.23736\/S0375-9393.21.15517-8","article-title":"Safety and efficacy of remimazolam compared with propofol in induction of general anesthesia","volume":"87","author":"Dai","year":"2021","journal-title":"Minerva Anestesiol"},{"key":"R7-20250702","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/LBR.0000000000000784","article-title":"Correlation of vital signs and depth of sedation by Modified Observer's Assessment of Alertness and Sedation (MOAA\/S) scale in bronchoscopy","volume":"29","author":"Pastis","year":"2022","journal-title":"J Bronchology Interv Pulmonol"},{"key":"R8-20250702","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2307\/2531453","article-title":"Interval estimation of the LD50 based on an up-and-down experiment","volume":"46","author":"Choi","year":"1990","journal-title":"Biometrics"},{"key":"R9-20250702","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1124\/dmd.116.072652","article-title":"Age-dependent absolute abundance of hepatic carboxylesterases (CES1 and CES2) by LC-MS\/MS proteomics: application to PBPK modeling of oseltamivir in vivo pharmacokinetics in infants","volume":"45","author":"Boberg","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"R10-20250702","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.bja.2021.05.027","article-title":"Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment","volume":"127","author":"St\u00f6hr","year":"2021","journal-title":"Br J Anaesth"},{"key":"R11-20250702","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bja.2022.02.040","article-title":"Pharmacodynamic analysis of intravenous bolus remimazolam for loss of consciousness in patients undergoing general anaesthesia: a randomised, prospective, double-blind study","volume":"129","author":"Chae","year":"2022","journal-title":"Br J Anaesth"},{"key":"R12-20250702","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.bja.2023.08.019","article-title":"Pharmacokinetics of remimazolam after intravenous infusion in anaesthetised children","volume":"131","author":"Gao","year":"2023","journal-title":"Br J Anaesth"},{"key":"R13-20250702","first-page":"2918","article-title":"Application of remimazolam in children during painless gastroscopy","volume":"41","author":"Cuicui","year":"2021","journal-title":"J Clin Pathol Res"},{"key":"R14-20250702","first-page":"140","article-title":"Determination of the half effective dose of remimazolam for sedation in pediatric patients during general anesthesia induction","volume":"45","author":"Zhihong","year":"2024","journal-title":"Int J Anesthesiol Resusc"},{"key":"R15-20250702","doi-asserted-by":"crossref","first-page":"1253738","DOI":"10.3389\/fmed.2023.1253738","article-title":"ED(95) of remimazolam in nasal administration for attenuating preoperative anxiety in children","volume":"10","author":"Long","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"R16-20250702","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2147\/DDDT.S401969","article-title":"Comparison of remimazolam tosilate and etomidate on hemodynamics in cardiac surgery: a randomised controlled trial","volume":"17","author":"Hu","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"R17-20250702","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00431-015-2689-z","article-title":"Evaluation and management of bradycardia in neonates and children","volume":"175","author":"Baruteau","year":"2016","journal-title":"Eur J Pediatr"},{"key":"R18-20250702","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"R19-20250702","doi-asserted-by":"crossref","first-page":"690875","DOI":"10.3389\/fphar.2021.690875","article-title":"Remimazolam: nonclinical and clinical profile of a new sedative\/anesthetic agent","volume":"12","author":"Kilpatrick","year":"2021","journal-title":"Front Pharmacol"},{"key":"R20-20250702","doi-asserted-by":"crossref","first-page":"193","DOI":"10.23736\/S0375-9393.21.16086-9","article-title":"Hiccup, a neglected side-effect of remimazolam bolus?","volume":"88","author":"Huang","year":"2022","journal-title":"Minerva Anestesiol"},{"key":"R21-20250702","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1097\/00000542-200112000-00014","article-title":"Are estimates of MAC reliable?","volume":"95","author":"Paul","year":"2001","journal-title":"Anesthesiology"},{"key":"R22-20250702","doi-asserted-by":"crossref","first-page":"110908","DOI":"10.1016\/j.jclinane.2022.110908","article-title":"Preoperative sedation in children with congenital heart disease: 50% and 95% effective doses, hemodynamic effects, and safety of intranasal dexmedetomidine","volume":"81","author":"Qiu","year":"2022","journal-title":"J Clin Anesth"}],"container-title":["European Journal of Anaesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/EJA.0000000000002183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:30:54Z","timestamp":1785785454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/EJA.0000000000002183"}},"subtitle":["An up-and-down sequential allocation trial"],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/eja.0000000000002183","relation":{},"ISSN":["0265-0215","1365-2346"],"issn-type":[{"value":"0265-0215","type":"print"},{"value":"1365-2346","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"2024-09-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}